Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction
| TENX Stock | USD 6.28 0.06 0.96% |
Slightly above 55% of Tenax Therapeutics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Tenax Therapeutics suggests that some traders are interested. Tenax Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Tenax Therapeutics' earnings reports, geopolitical events, and overall market trends.
Tenax |
Patent provides intellectual property protection until December 2040PH-HFpEF affects more than 1,600,000 North Americans, with estimates indicating a...
Read at globenewswire.com
 |
Tenax Therapeutics Fundamental Analysis
We analyze Tenax Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tenax Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tenax Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Retained Earnings
Retained Earnings Comparative Analysis
Tenax Therapeutics is currently under evaluation in retained earnings category among its peers. Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
Tenax Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Tenax Therapeutics stock to make a market-neutral strategy. Peer analysis of Tenax Therapeutics could also be used in its relative valuation, which is a method of valuing Tenax Therapeutics by comparing valuation metrics with similar companies.
Peers
Tenax Therapeutics Related Equities
| VRAX | Virax Biolabs | 27.98 | ||||
| SONN | Sonnet Biotherapeutics | 8.57 | ||||
| NRBO | Neurobo Pharmaceuticals | 1.42 | ||||
| ZVSA | ZyVersa Therapeutics | 0.81 | ||||
| DRMA | Dermata Therapeutics | 1.40 | ||||
| REVB | Revelation Biosciences | 1.54 | ||||
| UNCY | Unicycive Therapeutics | 2.56 | ||||
| WINT | Windtree Therapeutics | 3.13 | ||||
| ALLR | Allarity Therapeutics | 3.77 | ||||
| QNRX | Quoin Pharmaceuticals | 4.29 | ||||
| ADTX | Aditxt | 4.76 | ||||
| ENSC | Ensysce Biosciences | 5.79 |
Additional Tools for Tenax Stock Analysis
When running Tenax Therapeutics' price analysis, check to measure Tenax Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenax Therapeutics is operating at the current time. Most of Tenax Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenax Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenax Therapeutics' price. Additionally, you may evaluate how the addition of Tenax Therapeutics to your portfolios can decrease your overall portfolio volatility.